Imjudo & Imfinzi PMS
Study identifier:D419CR00029
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Will Be Recruiting
Official Title
Imjudo & Imfinzi Post-Marketing Surveillance
Medical condition
Hepatocellular Carcinoma
Phase
N/A
Healthy volunteers
No
Study drug
-
Sex
All
Estimated Enrollment
246
Study type
Observational
Age
n/a - n/a
Date
Study Start Date: 30 Dec 2024
Estimated Primary Completion Date: 28 Feb 2029
Estimated Study Completion Date: 28 Feb 2029
Study design
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Jul 2024 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
